Arax Advisory Partners’s Aimmune Therapeutics AIMT Stock Holding History

Arax Advisory Partners’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-800	Closed	-$13K	–	725
2020 Q2	$13K	Hold	800	–	–	﹤0.01%	514
2020 Q1	$12K	Hold	800	–	–	﹤0.01%	514
2019 Q4	$27K	Hold	800	–	–	0.01%	396
2019 Q3	$17K	Hold	800	–	–	0.01%	423
2019 Q2	$17K	Buy	+800	New	+$16.5K	0.01%	428
2018 Q4	$19K	Hold	800	–	–	0.01%	380
2018 Q3	$22K	Buy	+800	New	+$22.6K	0.01%	395

Other funds holding AIMT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return

WIC

Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Arax Advisory Partners's AIMT Position: Q3 2020 in Review

Arax Advisory Partners sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 800 shares — an estimated $13K sold.

Arax Advisory Partners first reported a position in AIMT in Q3 2018 and held it in 7 quarters. The position peaked at $27K in Q4 2019. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

Arax Advisory Partners reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
Arax Advisory Partners sold 800 Aimmune Therapeutics shares in Q3 2020, an estimated $13K.
Arax Advisory Partners first reported a position in Aimmune Therapeutics in Q3 2018 and held it in 7 quarters.
Arax Advisory Partners's Aimmune Therapeutics position peaked at $27K in Q4 2019.
188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on Arax Advisory Partners's 13F filing for Q3 2020, filed 12 Nov 2020.